Elenagen’s indirect mechanism offers new hope in cancer and inflammation treatment

June 15, 2024 Elenagen's indirect mechanism offers new hope in cancer and inflammation treatment In the article " Healing by Proxy: Newly Discovered Drug May Treat Cancer and Inflammation Through Indirect Action ," eCancer highlights the collaborative research between the University of Camerino and CureLab Oncology. The study reveals that Elenagen, a circular DNA encoding the p62/SQSTM1 protein, reprograms aged, pro-inflammatory stem cells into youthful, anti-inflammatory ones. This transformation leads to the secretion of beneficial factors that mimic Elenagen's effects, offering potential treatments for cancer and age-related inflammatory diseases. eCancer is a reputable platform dedicated to oncology news and education. Its coverage of Elenagen's novel mechanism underscores the significance of CureLab Oncology's research in developing innovative therapies. The article emphasizes the potential of Elenagen to revolutionize treatments for cancer and inflammation, highlighting CureLab Oncology's commitment to advancing medical science. Share Related posts September 3, 2026 Hormone-resistant prostate and breast cancers added to clinical study based on encouraging preliminary results Read more Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.

The release as fetched from its publisher. curelaboncology.com ↗